LEO Pharma has chosen to use Veeva Development Cloud’s Vault Clinical, Vault RIM and Vault Quality suites to unify drug development on a single cloud platform and collate clinical, regulatory, and quality applications for even greater efficiency and compliance throughout the product development lifecycle.
Rik Van Mol, vice president of Veeva Development Cloud Strategy, Europe, said: “LEO Pharma is a great example of how organizations are modernizing critical business functions. Development Cloud gives life sciences companies the foundation to eliminate system, site, and country silos throughout drug development.”
“LEO Pharma embraces Veeva Development Cloud.“
Mika Välilä, LEO’s senior director of digital business platforms, global IT, said: “Veeva is helping us transform our entire R&D business. Veeva Development Cloud allows us to drive greater consistency and productivity across product development efforts in clinical trials, regulatory matters, and quality.”
Kim Kjøller, LEO’s executive vice president of global research and development, said: “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline. Veeva Development Cloud gives us a unified platform that can enable us to maximize efficiency throughout product development and scale as we grow towards our goals. Now we will be able to streamline product development globally and speed up delivery of new treatments to even more patients.”